$DHR

UBS expects Thermo Fisher (TMO) to achieve 5-6% organic growth and 50-70 basis points of margin expansion, leading to double-digit EPS growth. Danaher (DHR) may return to mid-single-digit growth next year, potentially regaining its valuation premium over peers. Both companies could see improved performance due to operating leverage.

DHR Holding India, a subsidiary of Danaher Corporation, leased 1.8 lakh sq ft in Bengaluru's Whitefield for 5 years. The deal, worth ₹88 crore, reflects strong demand for large office spaces. DHR will pay ₹1.34 crore monthly, with 5% annual rent hikes. This follows similar large leases by Aon and Infineon, highlighting Whitefield's attractiveness for corporate occupiers.

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

Danaher Corp (DHR), a large-cap diagnostics & research company, has underperformed the Nasdaq Composite (NASX) with a 5.6% YTD decline, despite a 5.3% 52-week gain. DHR's Q2 earnings beat expectations, but shares fell 11% post-results due to slower respiratory testing and biotech sales. Analysts maintain a 'Strong Buy' rating with a $223.09 price target. Competitor Revvity Inc (RVTY) has outperformed with significant YTD and 52-week gains.

Danaher (DHR) has gained investor attention with a 10% rise over the past month and 18% over three months, reaching $216.07. Analysts estimate its fair value at $228.61, suggesting a 6% undervaluation. The company's focus on precision medicine and personalized therapies is expected to drive long-term growth, but risks include softer demand and policy pressures. Danaher's P/E ratio of 38.1x is higher than its fair ratio and peer average, indicating potential valuation risk.

Danaher (DHR) appoints Heathre Moler as Chief HR Officer effective 1 October 2026, replacing Georgeann Couchara. Moler has spent over a decade at Danaher. The company reported $24.6bn in 2025 revenue. Julie Sawyer Montgomery will also become CEO on the same date, succeeding Rainer Blair. Danaher recently acquired Masimo for $9.9bn and is pursuing StatLab.

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

Blair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.